IKBKB and neoplasm: However, the potential risks of on-target systemic toxicity, immunodeficiency and malignant development arising in contexts where IKKβ/NF-κB activity plays a dominant tumour suppressor role may prove insurmountable and forever undermine research efforts to clinically develop IKKβ-targeting therapeutics.